NOVAVAX INC Insider Trading for September 2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVAVAX INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NOVAVAX INC for September 2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 5.95 | 24,750 | 147,263 | 74,250 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 109.28 | 1,574 | 172,001 | 275 | 1.8 K to 275 (-85.13 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 108.39 | 3,419 | 370,586 | 1,849 | 5.3 K to 1.8 K (-64.90 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 107.30 | 7,061 | 757,643 | 5,268 | 12.3 K to 5.3 K (-57.27 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 106.18 | 5,975 | 634,437 | 1,239 | 7.2 K to 1.2 K (-82.83 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 117.07 | 546 | 63,918 | 18,304 | 18.9 K to 18.3 K (-2.90 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 116.08 | 941 | 109,228 | 18,850 | 19.8 K to 18.9 K (-4.75 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 115.23 | 992 | 114,310 | 19,791 | 20.8 K to 19.8 K (-4.77 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 113.81 | 397 | 45,184 | 20,783 | 21.2 K to 20.8 K (-1.87 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 113.02 | 720 | 81,377 | 21,180 | 21.9 K to 21.2 K (-3.29 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 111.92 | 213 | 23,840 | 21,900 | 22.1 K to 21.9 K (-0.96 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 110.97 | 2,320 | 257,459 | 22,113 | 24.4 K to 22.1 K (-9.50 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 109.98 | 8,052 | 885,550 | 24,433 | 32.5 K to 24.4 K (-24.79 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 109.07 | 6,595 | 719,304 | 32,485 | 39.1 K to 32.5 K (-16.88 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 108.20 | 3,702 | 400,546 | 39,079 | 42.8 K to 39.1 K (-8.65 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Sell | S | 107.22 | 273 | 29,271 | 42,781 | 43.1 K to 42.8 K (-0.63 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 5.95 | 24,750 | 147,263 | 43,054 | 18.3 K to 43.1 K (+135.22 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 5.95 | 25,000 | 148,750 | 75,000 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 109.21 | 1,100 | 120,126 | 1,561 | 2.7 K to 1.6 K (-41.34 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 108.39 | 3,145 | 340,889 | 2,661 | 5.8 K to 2.7 K (-54.17 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 107.30 | 5,789 | 621,140 | 5,806 | 11.6 K to 5.8 K (-49.93 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 106.17 | 9,915 | 1,052,689 | 11,595 | 21.5 K to 11.6 K (-46.09 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 117.07 | 551 | 64,503 | 21,510 | 22.1 K to 21.5 K (-2.50 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 116.08 | 951 | 110,389 | 22,062 | 23 K to 22.1 K (-4.13 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 115.23 | 1,003 | 115,577 | 23,012 | 24 K to 23 K (-4.18 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 113.81 | 401 | 45,639 | 24,015 | 24.4 K to 24 K (-1.64 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 113.02 | 727 | 82,168 | 24,416 | 25.1 K to 24.4 K (-2.89 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 111.92 | 216 | 24,175 | 25,143 | 25.4 K to 25.1 K (-0.85 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 110.97 | 2,343 | 260,012 | 25,358 | 27.7 K to 25.4 K (-8.46 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 109.98 | 8,133 | 894,458 | 27,701 | 35.8 K to 27.7 K (-22.70 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 109.07 | 6,661 | 726,503 | 35,834 | 42.5 K to 35.8 K (-15.67 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 108.20 | 3,739 | 404,549 | 42,496 | 46.2 K to 42.5 K (-8.09 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Sell | S | 107.22 | 276 | 29,593 | 46,235 | 46.5 K to 46.2 K (-0.59 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 5.95 | 25,000 | 148,750 | 46,510 | 21.5 K to 46.5 K (+116.23 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Option Exercise | M | 5.95 | 4,600 | 27,370 | 13,800 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Option Exercise | M | 5.95 | 25,000 | 148,750 | 75,000 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 109.12 | 2,432 | 265,383 | 7,337 | 9.8 K to 7.3 K (-24.90 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 108.08 | 4,751 | 513,480 | 9,769 | 14.5 K to 9.8 K (-32.72 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 107.05 | 5,653 | 605,133 | 14,520 | 20.2 K to 14.5 K (-28.02 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 106.04 | 5,485 | 581,634 | 20,173 | 25.7 K to 20.2 K (-21.38 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 117.07 | 551 | 64,503 | 25,658 | 26.2 K to 25.7 K (-2.10 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 116.08 | 951 | 110,389 | 26,210 | 27.2 K to 26.2 K (-3.50 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 115.23 | 1,003 | 115,577 | 27,160 | 28.2 K to 27.2 K (-3.56 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 113.81 | 401 | 45,639 | 28,163 | 28.6 K to 28.2 K (-1.40 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 113.02 | 727 | 82,168 | 28,564 | 29.3 K to 28.6 K (-2.48 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 111.92 | 216 | 24,175 | 29,291 | 29.5 K to 29.3 K (-0.73 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 110.97 | 2,343 | 260,012 | 29,506 | 31.8 K to 29.5 K (-7.36 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 109.98 | 8,133 | 894,458 | 31,849 | 40 K to 31.8 K (-20.34 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 109.07 | 6,661 | 726,503 | 39,982 | 46.6 K to 40 K (-14.28 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 108.20 | 3,739 | 404,549 | 46,643 | 50.4 K to 46.6 K (-7.42 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | S | 107.22 | 276 | 29,593 | 50,383 | 50.7 K to 50.4 K (-0.54 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Payment of Exercise | F | 111.18 | 2,103 | 233,812 | 50,658 | 52.8 K to 50.7 K (-3.99 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Sell | D | 111.18 | 247 | 27,461 | 52,761 | 53 K to 52.8 K (-0.47 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Buy | M | 5.95 | 4,600 | 27,370 | 53,008 | 48.4 K to 53 K (+9.50 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Buy | M | 5.95 | 25,000 | 148,750 | 48,408 | 23.4 K to 48.4 K (+106.80 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Option Exercise | M | 5.95 | 25,000 | 148,750 | 75,000 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Option Exercise | M | 5.95 | 25,000 | 148,750 | 75,000 | |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 109.25 | 1,000 | 109,251 | 32,727 | 33.7 K to 32.7 K (-2.96 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 108.40 | 1,112 | 120,544 | 33,727 | 34.8 K to 33.7 K (-3.19 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 107.25 | 1,000 | 107,248 | 34,839 | 35.8 K to 34.8 K (-2.79 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 106.22 | 1,000 | 106,224 | 35,839 | 36.8 K to 35.8 K (-2.71 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 117.07 | 551 | 64,503 | 36,839 | 37.4 K to 36.8 K (-1.47 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 116.08 | 951 | 110,389 | 37,390 | 38.3 K to 37.4 K (-2.48 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 115.23 | 1,003 | 115,577 | 38,341 | 39.3 K to 38.3 K (-2.55 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 113.81 | 401 | 45,639 | 39,343 | 39.7 K to 39.3 K (-1.01 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 113.02 | 727 | 82,168 | 39,744 | 40.5 K to 39.7 K (-1.80 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 111.92 | 216 | 24,175 | 40,471 | 40.7 K to 40.5 K (-0.53 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 110.97 | 2,343 | 260,012 | 40,687 | 43 K to 40.7 K (-5.45 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 109.98 | 8,133 | 894,458 | 43,030 | 51.2 K to 43 K (-15.90 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 109.07 | 6,661 | 726,503 | 51,163 | 57.8 K to 51.2 K (-11.52 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 108.20 | 3,739 | 404,549 | 57,824 | 61.6 K to 57.8 K (-6.07 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | S | 107.22 | 276 | 29,593 | 61,563 | 61.8 K to 61.6 K (-0.45 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Payment of Exercise | F | 111.18 | 11,429 | 1,270,676 | 61,839 | 73.3 K to 61.8 K (-15.60 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Sell | D | 111.18 | 1,338 | 148,759 | 73,268 | 74.6 K to 73.3 K (-1.79 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Buy | M | 5.95 | 25,000 | 148,750 | 74,606 | 49.6 K to 74.6 K (+50.40 %) |
| Sep 30 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Buy | M | 5.95 | 25,000 | 148,750 | 49,606 | 24.6 K to 49.6 K (+101.60 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Option Exercise | M | 0.00 | 6,546 | 0 | 13,092 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Payment of Exercise | F | 113.56 | 2,434 | 276,405 | 24,606 | 27 K to 24.6 K (-9.00 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Erck Stanley C | President and CEO | Buy | M | 0.00 | 6,546 | 0 | 27,040 | 20.5 K to 27 K (+31.94 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Option Exercise | M | 0.00 | 3,538 | 0 | 7,076 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Option Exercise | M | 0.00 | 31,900 | 0 | 0 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Payment of Exercise | F | 113.56 | 1,709 | 194,074 | 23,408 | 25.1 K to 23.4 K (-6.80 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Buy | M | 0.00 | 3,538 | 0 | 25,117 | 21.6 K to 25.1 K (+16.40 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Payment of Exercise | F | 113.56 | 15,408 | 1,749,732 | 21,579 | 37 K to 21.6 K (-41.66 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Trizzino John | EVP, CBO and CFO | Buy | M | 0.00 | 31,900 | 0 | 36,987 | 5.1 K to 37 K (+627.09 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Option Exercise | M | 0.00 | 38,588 | 0 | 0 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Payment of Exercise | F | 113.56 | 18,639 | 2,116,645 | 21,510 | 40.1 K to 21.5 K (-46.42 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Glenn Gregory M | President, R&D | Buy | M | 0.00 | 38,588 | 0 | 40,149 | 1.6 K to 40.1 K (+2,472.01 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 0.00 | 3,973 | 0 | 7,946 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Option Exercise | M | 0.00 | 30,900 | 0 | 0 | |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Payment of Exercise | F | 113.56 | 1,919 | 217,922 | 18,304 | 20.2 K to 18.3 K (-9.49 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 0.00 | 3,973 | 0 | 20,223 | 16.3 K to 20.2 K (+24.45 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Payment of Exercise | F | 113.56 | 14,925 | 1,694,883 | 16,250 | 31.2 K to 16.3 K (-47.87 %) |
| Sep 29 2020 | NVAX | NOVAVAX INC | Herrmann John A III | EVP, Chief Legal Of ... | Buy | M | 0.00 | 30,900 | 0 | 31,175 | 275 to 31.2 K (+11,236.36 %) |